Topic

#Treatment

24 articles
  1. Articles 1 Apr 2021 5 min read

    Ten Pearls for Performing Vitrectomy in Diabetic Retinopathy

    Important terms: Truncation: To relieve all the surrounding traction 360 degree Segmentation: Dividing a larger membranes/FVP into smaller islands of FVP by 360-degree truncation around them. Delamination: Separation of these membranes/FVP from the retinal surface to which they are firmly adherent by creating a plane of dissection between them. Pearl #1 When not to perform vitrectomy in diabetic retinopathy? Answer: In cases of extramacular tractional retinal detachment (TRD) when the fovea is attached and the patient has a comparative good vision the extramacular TRD can be observed. Charles and Flinn reported only 21% of extramacular TRD extending into macula without any surgical intervention. Also, DRVS (Diabetic retinopathy vitrectomy study) reports that only 23% of eyes with TRD developed severe visual loss at 2 years. Also, early intervention in such extramacular TRD’s can sometimes lead to more harm than benefit owing to the surgery itself. Pearl #2 First step should always be c

    Dr. Raja Narayan
  2. Interesting Reads 1 Apr 2021 16 min read

    Ten Clinical Trials in Retinal Diseases Every Postgraduate Should Know

    1. CATT (Comparison of Age-related Macular Degeneration Treatments Trials)1 Description A prospective, multicenter, single-blind, noninferiority randomized clinical trial. 1208 patients with neovascular AMD were enrolled from February 2008 and randomly assigned to receive intravitreal injections of ranibizumab (0.5 mg/0.05 ml) or bevacizumab (1.25 mg/0.05 ml) on either a monthly schedule or as needed with monthly evaluation. Patients aged ? 50 years with active, subfoveal CNV, fibrosis < 50% of total lesion area, visual acuity 20/25-20/320 and at least 1 drusen (>63?) in either eye or late AMD in fellow eye were eligible. The primary outcome was the mean change in visual acuity at 1 year, with a noninferiority limit of 5 letters on the eye chart. Results At one year, all four groups had similar improvements in visual acuity. Groups had similar rates of adverse events, though patients receiving bevacizumab had more occurrences of ?1 serious adverse event than those in the ranibizumab gr

    Dr. Neha Goel, MBBS MS MNAMS DNB FRCS (Glasgow)
  3. Articles 1 Apr 2021 23 min read

    Scleral Fixated Intraocular Lens Implantation- A Comprehensive Review

    Introduction Ideally a cataract surgery should result in the placement of an intraocular lens (IOL) within the capsular bag. However, this desirable outcome might be averted due to either preexisting zonular deficit or intraoperative posterior capsular tear, resulting in aphakia. This necessitates the need for an alternate means of IOL implantation. The surgeon can exercise the options of an anterior chamber IOL or iris fixated IOL or a scleral fixated IOL. Developments in IOL designs and modifications in implantation techniques have rendered them safe and efficacious. Recent studies have reported no significant differences in the postoperative visual recovery or complications rate between the 3 approaches.1 However, each option should be analyzed not only in accordance with surgeon’s experience but also with patient’s age, local, and systemic comorbidities.2 Scleral fixated IOL (SFIOL) involves sutured/sutureless fixation of the IOL to the sclera. SFIOL’s position closely approximates

    Dr. Dhanashree Ratra · Dr. Abhinav Dhami · +1 other
  4. Articles 1 Apr 2021 4 min read

    Ten Things You Should Know about Brolucizumab

    1. Brolucizumab is a humanized, single-chain variable fragment (scFv) antibody with a molecular mass of approximately 26 kDa that inhibits VEGF-A.[1] (An scFv is an autonomous binding agent that is no longer dependent on a heavy molecular support structure but still retains the full binding capacity to its target). Mechanism of Action of Brolucizumab Unique Properties of Brolucizumab 2. The pharmacokinetics of a single intravitreal (IVT) injection of Brolucizumab in cynomolgus monkeys revealed a mean terminal half-life of 2.4 ± 0.3 days in all ocular compartments. It was cleared from the serum with a mean half-life of 51 hours (approximately 2 days).[2] Brolucizumab Bevacizumab Ranibizumab Aflibercept Molecule Short-chain variable fragment Full antibody (IgG) Monoclonal humanized antibody format Fusion protein Clinical dose in neovascular ARMD 6 mg 1.25 mg* 0.5 mg 2 mg Equivalent Molar dose 11.2-13.3 0.4-0.5 0.5-0.6 1.0 Table: Molecular properties of anti-VEGF agents (ARMD= Age-related

    Dr. Anmol Naik

Other topics

Review Vitreoretina Top Ten Series Tips & Pearls Made Easy Macular Diseases Cornea and External Eye Diseases Must Read Preferred Practise Pattern Learn from Masters Uvea and Intraocular Inflammation Case Discussion Cataract Surgery i-File Pediatric Ophthalmology Glaucoma Imaging Grand Rounds infection